Research Article
Mitotane-Induced Hyperlipidemia: A Retrospective Cohort Study
Table 1
Demographic and clinical characteristics of the study patients.
| | Variable | |
| | Mean age at diagnosis, (±standard deviation) | 52.5 (±12.5) | | Sex, number of patients (%) | | | Male | 12 (31.6) | | Female | 26 (68.4) | | Race, number of patients (%) | | | White | 32 (84.2) | | Black | 3 (7.9) | | Hispanic | 3 (7.9) | | Median baseline body mass index, kg/m2 (range)* | 34.6 (20.3 to 54) | | ACC stage, number of patients (%) | | | I | 2 (5.3) | | II | 18 (47.4) | | III | 13 (34.2) | | IV | 5 (13.2) | | Functional status of ACC, number of patients (%) Functional | 15 (39.5) | | Hypercortisolism, number of patients (%) | 7 (18.4) | | Hyperaldosteronism, number of patients (%) | 6 (15.8) | | Hyperandrogenism, number of patients (%) | 2 (5.3) | | Nonfunctional, number of patients (%) | 23 (60.5) | | Mean baseline HDL-c, mg/dL (±standard deviation) | 53.3 (±16.3) | | Baseline lipid therapy, number of patients (%) | | | Yes | 10 (26.3) | | No | 28 (73.7) |
|
|
26 patients had information on BMI at baseline.
|
